Pathophysiology nke ọrịa cancer prostate na-ezo aka na usoro na usoro ndị na-eduga na mmepe na ọganihu nke ọrịa ahụ.
Ọrịa cancer prostate bụ ọrịa cancer na- emerụ ahụ nke na- esi n" mkpụrụ ndụ nke akwara prostate apụta , nke bụ́ obere akụkụ ahụ́ dị ka walnut nke dị n" okpuru ọkpụkpụ afọ n" ebe ụmụ nwoke nọ .
Akwara prostate na-emepụta mmiri ọmụmụ, bụ́ nke na-enye nri ma na-ebuga mkpụrụ ndụ ihe nketa.
A ghọtaghị kpọmkwem ihe na-akpata ọrịa cancer prostate n'ụzọ zuru ezu, ma a maara ọtụtụ ihe na-eme ka ihe ize ndụ nke ịrịa ọrịa ahụ dịkwuo elu.
Ihe ndị a na-agụnye afọ ndụ, akụkọ ihe mere eme nke ezinụlọ, agbụrụ, na mgbanwe ụfọdụ e nwere n'ahụ́ mmadụ.
Ọrịa cancer prostate na-emekarị n'etiti ndị ikom meworo agadi, ihe ka ọtụtụ n'ime ha na-adịkwa n'etiti ndị ikom karịrị afọ 65.
Tụkwasị na nke ahụ, ndị ikom nwere akụkọ ihe mere eme ezinụlọ nke ọrịa cancer prostate nọ n'ihe ize ndụ dị elu, dị ka ndị ikom Africa America na ndị ikom si Caribbean.
Pathophysiology nke ọrịa cancer prostate na-agụnye uto na nkewa nke mkpụrụ ndụ n'enweghị nchịkwa n'ime prostate gland.
Nke a nwere ike ime n'ihi mgbanwe mkpụrụ ndụ ihe nketa nke na- eduga n' igosipụta ihe ụfọdụ na- akpata uto n' ụzọ gabigara ókè ma ọ bụ n' igbochi mkpụrụ ndụ ihe nketa ndị na- egbochi ọrịa.
Mgbanwe ndị a pụrụ ime ka mkpụrụ ndụ na- eto n" ụzọ a na- achịkwaghị achịkwa , na- eduga n" imepụta akpụ .
Ka ọrịa ahụ na-etolite, ọ pụrụ ịwakpo akwara na akụkụ ahụ ndị dị nso, dị ka akwara, rectum, na lymph nodes ndị dị nso.
N'ọnọdụ ụfọdụ, mkpụrụ ndụ kansa pụrụ isi n'ụbụrụ mbụ ahụ pụọ ma gbasaa n'akụkụ ndị ọzọ nke ahụ site n'ọbara ma ọ bụ n'usoro lymphatic, usoro a maara dị ka metastasis.
Ozugbo ọrịa cancer ahụ gbasasịrị, ọ pụrụ isi ike ịgwọ ya.
A pụkwara imetụta ọrịa cancer prostate site n'ihe ndị na-akpata hormone, karịsịa hormone androgen bụ́ testosterone.
Testosterone pụrụ ịkpali uto nke mkpụrụ ndụ cancer prostate, ọtụtụ ọgwụgwọ maka ọrịa cancer prostate na-achọkwa ibelata ọkwa nke hormone a ma ọ bụ igbochi mmetụta ya.
N'ikwu ya n'ụzọ dị nkenke, pathophysiology nke ọrịa cancer prostate na-agụnye uto na nkewa nke mkpụrụ ndụ n'ime prostate gland, nke ihe ndị metụtara mkpụrụ ndụ ihe nketa, hormone, na gburugburu ebe obibi pụrụ imetụta.
Ịghọta usoro ndị dị n'okpuru ọrịa ahụ dị oké mkpa maka ịzụlite ọgwụgwọ ndị dị irè na imeziwanye nsonaazụ maka ndị ọrịa nwere ọrịa cancer prostate.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
Nkwupụta: ọgwụgwọ
A na-enye weebụsaịtị a maka ebumnuche agụmakwụkwọ na ozi naanị ma ọ bụghị inye ndụmọdụ ahụike ma ọ bụ ọrụ ọkachamara.
E kwesịghị iji ihe ọmụma e nyere mee ihe maka ịchọpụta ma ọ bụ ịgwọ nsogbu ahụ ike ma ọ bụ ọrịa, ndị na-achọ ndụmọdụ ahụike onwe ha kwesịrị ịgakwuru dọkịta nwere ikike.
Biko rịba ama na netwọkụ akwara nke na-emepụta azịza nye ajụjụ ndị ahụ, bụ ihe na-ezighi ezi mgbe ọ na-abịa na ọnụọgụ ọnụọgụ. Dịka ọmụmaatụ, ọnụọgụ ndị mmadụ chọpụtara na ọrịa akọwapụtara.
Na-achọkarị ndụmọdụ nke dọkịta gị ma ọ bụ onye na-ahụ maka ahụike ọzọ ruru eru banyere ọnọdụ ahụike. Elegharala ndụmọdụ ahụike ọkachamara anya ma ọ bụ na-egbu oge n'ịchọ ya n'ihi ihe ị gụrụ na weebụsaịtị a. Ọ bụrụ na i chere na ị nwere ike ịnweta mberede ahụike, kpọọ 911 ma ọ bụ gaa n'ọnụ ụlọ mberede kacha nso ozugbo. Enweghị mmekọrịta dọkịta na onye ọrịa na-emepụta site na weebụsaịtị a ma ọ bụ ojiji ya. Ma BioMedLib ma ndị ọrụ ya, ma onye ọ bụla na-enye aka na weebụsaịtị a, anaghị eme nkwupụta ọ bụla, kwupụta ma ọ bụ kwupụta, gbasara ozi enyere ebe a ma ọ bụ ojiji ya.
Nkwupụta: ikike nwebisiinka
Digital Millennium Copyright Act nke 1998, 17 U.S.C. § 512 (DMCA) na-enye ohere maka ndị nwe ikike nwebisiinka nke kwenyere na ihe na-apụta na ịntanetị na-emebi ikike ha n'okpuru iwu ikike nwebisiinka US.
Ọ bụrụ na ị kwenyere n'ezi okwukwe na ọdịnaya ma ọ bụ ihe ọ bụla enyere na njikọ nke weebụsaịtị anyị ma ọ bụ ọrụ na-emebi ikike nwebisiinka gị, gị (ma ọ bụ onye nnọchi anya gị) nwere ike iziga anyị ọkwa na-arịọ ka ewepụ ọdịnaya ma ọ bụ ihe, ma ọ bụ gbochie ịnweta ya.
A ghaghị izipu ọkwa n'akwụkwọ site na email (lee ngalaba "Kọntaktị" maka adreesị email) .
DMCA na-achọ ka ọkwa gị banyere mmebi iwu nwebisiinka na-ekwu na ọ gụnyere ozi ndị a: (1) nkọwa nke ọrụ nwebisiinka nke bụ isiokwu nke mmebi iwu a na-ekwu; (2) nkọwa nke ihe a na-ekwu na ọ na-emebi iwu na ozi zuru ezu iji mee ka anyị chọta ọdịnaya ahụ; (3) ozi kọntaktị maka gị, gụnyere adreesị gị, nọmba ekwentị na adreesị email; (4) nkwupụta site n'aka gị na ị nwere ezi okwukwe na ọdịnaya n'ụzọ a na-eme mkpesa na ọ bụghị ikike site n'aka onye nwe ikike, ma ọ bụ onye nnọchi anya ya, ma ọ bụ site na ọrụ iwu ọ bụla;
(5) nkwupụta site n'aka gị, nke ị bịanyere aka na ya n'okpuru ntaramahụhụ nke ịgba akaebe ụgha, na ozi dị na ọkwa ahụ ziri ezi na na ị nwere ikike iji mezuo ikike nwebisiinka nke a na-ekwu na emebi;
na (6) mbinye aka nkịtị ma ọ bụ nke elektrọnik nke onye nwe ikike ma ọ bụ onye e nyere ikike ime ihe n'aha onye nwe ikike.
Ọ bụrụ na i tinyeghị ozi niile dị n'elu, ọ nwere ike ime ka a na-egbu oge n'ịhazi mkpesa gị.
Mkparịta ụka
Biko zitere anyị email na ajụjụ ọ bụla / aro.
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
